Author

Chiagozie Ifeoma Pickens

Northwestern UniversityORCID 0000-0002-3400-9228Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Alexander V. MishariniD· 2 shared Alvaro DonayreiD· 2 shared Anna E. PawlowskiiD· 2 shared Benjamin David SingeriD· 2 shared Catherine A. GaoiD· 2 shared G. R. Scott BudingeriD· 2 shared Helen K. DonnellyiD· 2 shared Hiam Abdala‐ValenciaiD· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Alexander V. MisharinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintMay 14, 2026

Pathogen-specific host responses define distinct pneumonia endotypes in the human lung

Nikolay S. Markov, Marcin Możejko, Vijeeth Guggilla…·The NU SCRIPT Study Investigators

This study identifies distinct pneumonia endotypes based on pathogen-specific host responses in the lung, linking them to clinical outcomes and suggesting personalized treatment strategies.

2 citations

humanscRNA-seq

Systems BiologyNature ImmunologyPeer-reviewedAug 13, 2024

A distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia

Nikolay S. Markov, Ziyou Ren, Karolina J. Senkow…·Karen M. Ridge

The paper examines alveolar T cell responses in SARS-CoV-2 pneumonia patients, finding that early interferon signaling and targeting of structural proteins correlate with better clinical outcomes.

17 citationstop 3%

humanbulk RNA-seq